Health Economics›Marginal zone lymphoma›First-line therapy

First-line therapy

Marginal zone lymphoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	~44.1 mo	—	~2	~R 163 929 PFS proxy · indirect	15
Fludarabine monotherapy Variant #05	—	R 13 754	28d	—	—	6	R 82 524 PFS proxy	1
Chlorambucil monotherapy Variant #03	—	R 2 355	28d	—	69.5 mo	13	R 30 610 PFS proxy	1
Ibritumomab tiuxetan protocol Variant #18 Partial	—	—	8d	~36.5 mo	—	~1	—	1

4 of 4 regimens shown